An interview with one of the recipients of NHF's Innovative Investigator Awards
PrintFriendly
-
NHF 70th: Pursuing Discovery of the Next Generation of Therapies
-
Sangamo Reports Positive Preliminary Data from Hemophilia Gene Therapy Trial
The company reported on preliminary data from the Phase 1/2 clinical trial designed to evaluate SB-525, the company’s gene therapy program for people with hemophilia A, or factor VIII (FVIII) deficiency.
-
New Medscape Activity Features the Science Behind Gene Therapy
The activity will examine the technology behind the emerging approaches to gene therapy in hemophilia.
-
Court Rules on Shire/Roche Preliminary Injunction
The preliminary injunction was part of an ongoing patent lawsuit.
-
Spark Reports Progress on Hemophilia A Gene Therapy
The therapy is administered via a one-time intravenous infusion, which is designed to elicit the production of therapeutic levels of factor VIII.
-
Shire Discontinuing Manufacture and Distribution of BEBULIN®
The company stated that it is their intent to provide enough advanced notice of the discontinuation to allow patients to transition to a suitable alternative therapy
-
Inhibitor Webinar for Providers Available Now!
This CME and CNE-accredited activity reviews the basic science behind the development of inhibitor antibodies to treatment for hemophilia, and more.
-
New Financial Assistance Program Available for Hemophilia Patients
A new patient financial assistance program has become available for individuals with hemophilia.